Overview
All participants will be tested for EBV-related biomarkers, including EBNA1-IgA, VCA-IgA, and BNLF2b total antibody (P85-Ab), and participants with high serologic risk will be selected based on serologic test results, and dual-energy CT will be performed first for high-risk screening subjects, and dual-energy CT will be performed first for the high-risk group to record dual-energy CT examinations of those suspected of nasopharyngeal carcinoma, and then endoscopy was performed on the high-risk group to record those suspected of nasopharyngeal carcinoma under endoscopy, and finally biopsies were taken for positive lesion sites indicated by dual-energy CT and suspicious lesion sites found by endoscopy to clarify the diagnosis.
Eligibility
Inclusion Criteria:
- Subject residents in Zhongshan City
- Subject has no medical record of nasopharyngeal carcinoma
- Subject is able to comprehend, sign, and date the written informed consent document to participate in the study
- Subject has psychical condition and well consciousness, and also accept and cooperate with the follow-up of this study
Exclusion Criteria:
- Subject has heavy cardiovascular, liver or kidney disease
- Subject has contraindications to nasopharyngeal endoscopy
- Subject has contrast media allergy